Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Sun Yat-sen University describes mesenchymal stem cells overexpressing CCR2

April 29, 2019

Clotbuster's clot-busting may be beside the point

April 29, 2019

Pimavanserin begins phase III for major depressive disorder

April 26, 2019

Takeda identifies glutamate receptor agonists

April 26, 2019

Unexpected role of reduced myelination in Williams syndrome

April 26, 2019

Glycosylation controls proteasome activity via sequence editing

April 25, 2019

Teva discontinues development of fremanezumab for cluster headaches

April 24, 2019

MGL inhibitors revealed in Takeda Pharmaceutical patent

April 24, 2019

Nanjing TransThera Biosciences patents PDE9 inhibitors

April 24, 2019

Sunshine Lake Pharma divulges 5-HT1A receptor agonists

April 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.